Head-To-Head Comparison: Rockwell Medical (NASDAQ:RMTI) and LexaGene (OTCMKTS:LXXGF)

LexaGene (OTCMKTS:LXXGF) and Rockwell Medical (NASDAQ:RMTI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Ratings

This is a summary of current ratings and target prices for LexaGene and Rockwell Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LexaGene	0	0	0	0	0.00
Rockwell Medical	1	0	1	0	2.00

Rockwell Medical has a consensus price target of $20.00, indicating a potential upside of 192.83%. Given Rockwell Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Rockwell Medical is more favorable than LexaGene.

Institutional & Insider Ownership

23.3% of Rockwell Medical shares are held by institutional investors. 4.6% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares LexaGene and Rockwell Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LexaGene	N/A	N/A	N/A
Rockwell Medical	-7.98%	-15.41%	-9.62%

Valuation and Earnings

This table compares LexaGene and Rockwell Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LexaGene	N/A	N/A	N/A	N/A	N/A
Rockwell Medical	$67.68 million	0.40	-$5.31 million	($1.50)	-4.55

LexaGene has higher earnings, but lower revenue than Rockwell Medical.

Summary

Rockwell Medical beats LexaGene on 6 of the 9 factors compared between the two stocks.

About LexaGene

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.